Explore the Agenda
7:10 am Check In & Morning Coffee
8:20 am Chair’s Opening Remarks
Unlocking the Next Chapter of mRNA Therapeutics by Expanding Indications Enhancing Delivery & Advancing Novel RNA Modalities
8:30 am Advancing Targeted Delivery & Respiratory Formulations to Enable mRNA Applications in Hard-to-Reach Tissues
- Exploring advances in organ-specific mRNA delivery, including inhalation, intranasal, and systemic routes
- Examining emerging lipid and polymer systems designed for non-hepatic targeting
- Review case studies and clinical updates from respiratory and extrahepatic mRNA programs
9:00 am Presentation Reserved for ReciPharm AB
9:30 am Polymeric Delivery Systems for mRNA Demonstrating Translational Potential with In Vivo Case Studies
- Explore how polymer-based delivery systems compare to LNPs in terms of stability, targeting, and immunogenicity
- Review in vivo data showcasing the performance of polymeric carriers in delivering mRNA to specific tissues
- Understand the implications of polymeric delivery platforms for expanding mRNA applications beyond vaccines
10:00 am Morning Break & Speed Networking
Join our speed networking session tailored for mRNA experts, like yourselves, to connect with industry peers and facilitating rapid yet meaningful exchanges of insights and expertise. Elevate your networking experience during this session designed for impactful connections among mRNA experts and stakeholders
Track A: Pre-Clinical & Clinical Development
Follow the journey from early discovery to first-in-human trials, uncovering how smarter pre-clinical models and clinical strategies are accelerating safe, effective mRNA therapies to patients
Chair:
11:00 am Advancing mRNA-LNP Technology to Enable Safer and More Effective CAR Cell Therapies
- Explore how mRNA-LNP platforms enhance the precision and safety of CAR cell engineering
- Review preclinical advances demonstrating improved efficacy and reduced toxicity in CAR-based therapies
- Understand the translational potential of transient mRNA delivery to overcome current limitations in cell therapy
11:30 am Presentation Reserved for Sartorius BIA Separations
12:00 pm Tumour-on-a-Chip Systems to Advance Targeted LNP Delivery for mRNA Therapeutics
- Explore how tumour-on-a-chip platforms provide physiologically relevant models to test LNP targeting and efficacy
- Review case studies demonstrating improved predictability of delivery outcomes compared to conventional in vitro assays
- Understand how these systems accelerate candidate optimization and reduce translational risks in oncology applications
12:30 pm Advancing Local mRNA Delivery for Bone & Tendon Regeneration
- Explore preclinical strategies that enable efficient local delivery of mRNA to hard-to-reach musculoskeletal tissues such as bone and tendon
- Learn how pharmacology package completion supports safety, efficacy, and translational readiness for regenerative indications
- Understand the implications of localised delivery on reducing systemic exposure while enhancing therapeutic outcomes in tissue repair
Track B: Technology Innovation & Manufacturing
Explore the breakthroughs in mRNA design, delivery systems, and scalable manufacturing that are transforming innovation into reliable, clinic-ready products
Chair:
11:00 am Optimizing mRNA Architecture to Improve Translation Efficiency Stability & Manufacturability at Scale
- Explore how modifications to UTRs, polyA tails, and 5’ capping structures impact expression and translational fidelity
- Learn from case studies optimizing non-coding elements to improve stability and protein yield across platforms
- Understand the design principles behind scalable constructs that remain compatible with standardized GMP production
11:30 am Presentation Reserved for Vazyme
12:00 pm Developing Scalable Screening Technologies to Accelerate LNP Design from Bench to Bedside
- Explore high-throughput screening innovations that streamline the identification of optimal LNP formulations
- Learn how scalable platforms enable efficient transition from discovery to clinical-grade manufacturing
- Understand how technology transfer strategies are bridging preclinical development with clinical translation
12:30 pm Unlocking the Potential of Chemically Synthesized mRNA
- Explore how chemical synthesis is overcoming traditional in vitro transcription bottlenecks
- Understand the potential advantages of chemically synthesized mRNA to test new nucleotide modifications and ease the production of individualized anticancer vaccines
- Learn from emerging preclinical and translational case studies where chemically synthesized mRNA is expanding therapeutic opportunities
- Identify issues and potential solutions for the use of chemical synthesis to make mRNAs
1:00 pm Lunch & Networking
Track A: Pre-Clinical & Clinical Development
Follow the journey from early discovery to first-in-human trials, uncovering how smarter pre-clinical models and clinical strategies are accelerating safe, effective mRNA therapies to patients
2:00 pm Optimizing In Vivo Delivery & Dosing Strategies to Maximize mRNA Therapeutic Efficacy & Safety
- Comparing systemic vs local delivery strategies for achieving tissue-specific expression
- Examining how lipid type, ionizable components, and dosing schedule impact safety and immunogenicity
- Reviewing preclinical to clinical case studies where formulation or dosing adjustments significantly impacted trial outcomes
2:30 pm mRNA Based Therapy in Heart Failure
- Advances in mRNA applications for heart failure
- Delivery strategies to target cardiac tissue
- Pathways to clinical translation and approval
Track B: Technology Innovation & Manufacturing
Explore the breakthroughs in mRNA design, delivery systems, and scalable manufacturing that are transforming innovation into reliable, clinic-ready products
2:00 pm Expanding mRNA Therapeutic Horizons to Unlock New Targets Tissues & Indications Beyond Infectious Disease
- FlashRNA®: A disruptive RNA delivery technology for nextgeneration therapies
- Discovering how mRNA is being applied to oncology, cardiovascular disease, and rare genetic conditions
- Learning from companies breaking away from the vaccine narrative to pursue non-infectious targets
2:30 pm High-Throughput Nanoformulation Screening to Accelerate R&D & De-Risk Development
- Rapidly evaluate diverse nano formulations to identify optimal candidates early
- Streamline delivery design with data-driven screening approaches
- Minimize late-stage failures by de-risking formulation decisions in preclinical R&D
3:00 pm Poster Session & Afternoon Break
This poster session is your go-to session to obtain competitive insights and present your most innovative work to mRNA thought leaders and stakeholders. For more information or to submit your abstract, please email info@hansonwade.com
Fueling the Future of mRNA Through Smart Capital & Strategic Collaboration
From billion-euro megadeals to targeted niche investments, Europe’s mRNA landscape is surging. BioNTech’s $1.25B acquisition of CureVac and Cipla’s €3M boost for Ethris GmbH are reshaping the competitive and therapeutic landscape. These landmark moves set the stage for critical conversations in this session on how strategic capital and collaboration can unlock the next wave of mRNA innovation
4:00 pm Panel Discussion: De-Risking mRNA Innovation to Attract Investment & Partnerships in a Post-Vaccine Era
- What makes an mRNA therapeutic platform fundable in 2026? What clinical and strategic proof do VCs want to see?
- How are biotech leaders navigating delivery licensing limitations, high COGS, and regulatory uncertainty to stay attractive to partners?
- Are non-US trial strategies, earlier pharma engagement, or new reimbursement models the key to investor re-engagement?
4:30 pm Reviving Investor Confidence in mRNA by Proving Clinical Value Beyond Vaccines & Building De-Risked Development Plans
- Identifying the clinical and strategic proof points investors expect before committing capital especially in oncology and rare disease
- Learning how to differentiate from vaccine legacy perception and position your platform for long-term, non-pandemic relevance
- Understanding the importance of having a clear development and reimbursement roadmap from day one, not post-funding